Cardiovascular effects of an ultra-short-acting nitric oxide-releasing compound, zwitterionic diamine/NO adduct, in dogs

Circulation

Volumn 94, Issue 9, 1996, Pages 2235-2240

  Zhang, Ping ^a   Ohara, Akitoshi ^a   Mashimo, Takashi ^a   Sun, Jianhua ^a   Shibuta, Satoshi ^a   Takada, Koji ^a   Kosaka, Hiroaki ^a   Terada, Masaru ^a   Yoshiya, Ikuto ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

endothelium derived factors; hemodynamics; nitroglycerin; vasodilation

Indexed keywords

GLYCERYL TRINITRATE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; NOC 7; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ARTICLE; BLOOD FLOW VELOCITY; CAROTID ARTERY FLOW; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; HEART OUTPUT; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; LIVER BLOOD FLOW; LUNG BLOOD FLOW; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE; VASODILATATION;

EID: 0029802358     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.9.2235     Document Type: Article

References (39)

1. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84:9265-9269.
2. Palmer RMJ, Ferrige AG, Moncada SA. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
3. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
4. Ignarro LJ, Ross G, Tillisch J. Pharmacology of endothelium-derived nitric oxide and nitrovasodilators. West J Med. 1991;154:51-62.
5. Moncada S, Palmer RMJ, Higgs EA. The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension. 1988;12:365-372.
6. Oilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY: Pergamon Press; 1990:803-805.
7. Mangione NJ, Glasser SP. Phenomenon of nitrate tolerance. Am Heart J. 1994;128:137-146.
8. Hrabie JA, Klose JR, Wink DA, Keefer LK. New nitric oxide-releasing zwitterions derived from polyamines. J Org Chem. 1993;58:1472-1476.
9. Shibuta S, Mashimo T, Ohara A, Zhang P, Yoshiya I. Intracerebro-ventricular administration of a nitric oxide-releasing compound, NOC-18, produces thermal hyperalgesia in rats. Neurosci Lett. 1995;187:1-4.
10. Shimaoka M, Iida T, Ohara A, Taenaka N, Mashimo T, Honda T, Yoshiya I. NOC, a nitric-oxide-releasing compound, induces dose dependent apoptosis in macrophages. Biochem Biophys Res Commun. 1995;208:519-526.
11. McCall T, Vallance P. Nitric oxide takes centre-stage with newly defined roles. Trends Pharmacol Sci. 1992;13:1-6.
12. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science. 1992;258:1898-1902.
13. 15N]nitrate in biological fluids. Anal Biochem. 1982;126:131-138.
14. Kosaka H, Sawai Y, Sakaguchi H, Kumura E, Harada N, Watanabe M, Shiga T, ESR spectral transition by arteriovenous cycle in nitric oxide hemoglobin of cytokine-treated rats. Am J Physiol. 1994;266:C1400-C1405.
15. Seto Y, Tsunoda N, Ohta H, Shinohara T. Determination of blood cyanide by head space gas Chromatography with nitrogen-phosphorus detection and using a megabore capillary column. Anal Chim Acta. 1993;276:247-259.
16. Husain M, Adrie C, Ichinose F, Kavosi M, Zapol WM. Exhaled nitric oxide as a marker for organic nitrate tolerance. Circulation. 1994;89:2498-2502.
17. Vanderford PA, Wong J, Chang R, Keefer LK, Soifer SJ, Fineman JR. Diethylamine/nitric oxide (NO) adduct, an NO donor, produces potent pulmonary and systemic vasodilation in intact newborn lambs. J Cardiovasc Pharmacol. 1994;23:113-119.
18. Ragsdale RO, Karstetter BR, Drago RS. Decomposition of the adducts of diethylamine and isopropylamine with nitrogen(II) oxide. Inorg Chem. 1965;4:420-422.
19. Miletich DJ, Ivankovich AD. Sodium nitroprusside and cardiovascular hemodynamics. Int Anesthesiol Clin. 1978;16:31-49.
20. Feelisch M. The biochemical pathways of nitric oxide formation from nitrovasodilators: appropriate choice of exogenous NO donors and aspects of preparation and handling of aqueous NO solutions. J Cardiovasc Pharmacol. 1991;17(suppl 3):S25-S33.
21. G-Methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo? Biochem Biophys Res Commun. 1989;160:881-886.
22. Adams AP, Clarke NS, Edmonds-Deal J. Effects of sodium nitroprusside on myocardial contractility and hemodynamics. Br J Anaesth. 1973;45:120. Abstract.
23. Chatterjee K, Parmley WW, Ganz W, Forrester J, Walinsky P, Crexells C, Swan C. Hemodynamic and metabolic responses to vasodilator therapy in acute myocardial infarction. Circulation. 1973;48:1183-1193.
24. Kien ND, White DA, Reitan JA, Eisele J. Cardiovascular function during controlled hypotension induced by adenosine triphosphate or sodium nitroprusside in the anesthetized dog. Anesth Analg. 1987;66:103-110.
25. Colley PS, Sivarajan M. Regional blood flow in dogs during halothane anesthesia and controlled hypotension produced by nitroprusside or nitroglycerin. Anesth Analg. 1984;63:503-510.
26. Turner JM, Powell D, Gibson RM, McDowall DG. Intracranial pressure changes in neurosurgical patients during hypotension induced with sodium nitroprusside or trimethaphan. Br J Anaesth. 1977;49:419-425.
27. Curry SC, Arnold-Capell P. Nitroprusside, nitroglycerin, and angiotension-converting enzyme inhibitors. Crit Care Clin. 1991;7:555-581.
28. Michenfelder JD, Tinker JH. Cyanide toxicity and thiosulfate protection during chronic administration of sodium nitroprusside in the dog: correlation with a human case. Anesthesiology. 1977;47:441-448.
29. Ivankovich AD, Braverman B, Shulman M, Klowden AJ. Prevention of nitroprusside toxicity with thiosulfate in dogs. Anesth Analg. 1982;61:120-126.
30. Tinker JH, Michenfelder JD. Increased resistance to nitroprusside induced cyanide toxicity in anuric dogs. Anesthesiology. 1980;52:40-47.
31. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317:799-804.
32. Zimrin D, Reichek N, Bogin KT, Aurigemma G, Douglas P, Berko B, Fung H-L. Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation. 1988;77:1376-1384.
33. Jordan RA, Seth L, Casebolt P, Hayes MJ, Wilen MM, Franciosa J. Rapidly developing tolerance to transdermal nitroglycerin in congestive heart failure. Ann Intern Med. 1986;104:295-298.
34. Van de Voorde J. Mechanisms involved in the development of tolerance to nitrovasodilators. J Cardiovasc Pharmacol. 1991;17(suppl 3):S304-S308.
35. Waldman SA, Rapoport RM, Ginsburg R, Murad F. Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochem Pharmacol. 1986;35:3525-3531.
36. Bigatello LM, Hurford WE, Kacmarek RM, Roberts JD, Zapol WM. Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome. Anesthesiology. 1994;80:761-770.
37. Rush ML, Lang WJ, Rand MJ. Studies on compensatory reflexes and tolerance to glyceryl trinitrate (GTN). Eur J Pharmacol. 1971;16:148-155.
38. Münzel T, Holtz J, Mülsch A, Stewart DJ, Bassenge E. Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist. Circulation. 1989;79:188-197.
39. Kosaka H, Uozumi M, Tyuma I. The interaction between nitrogen oxides and hemoglobin and endothelium-derived relaxing factor. Free Radic Biol Med. 1989;7:653-658.